VivoSeq
Other

Hand-Foot Syndrome

12

Pipeline Programs↗

2

Active Trials↗

8

Companies Involved↗

Hand-foot syndrome is an emerging landscape with 12 programs across 8 companies. The most active players are Nanometics (d.b.a. PHD Biosciences), AbbVie, Alnylam Pharmaceuticals. 1 therapy is approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

80/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Nanometics (d.b.a. PHD Biosciences)

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Pfizer logo

Pfizer

2 programs

Phase 2Roche logo

Roche

1 program

Phase 3A

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

13

clinical trials

Completed8 · 62%
Recruiting2 · 15%
Terminated2 · 15%
Unknown status1 · 8%

Clinical Trials

Trial Activity

13 trials

Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome
Recruiting·—·N/A·NCT06602167·220 enrolled
The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs
Recruiting·PPeking University Cancer Hospital & Institute·N/A·NCT06583369·220 enrolled
Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome
Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 2·NCT01609166·60 enrolled
Study of Pyridoxine for Hand-Foot Syndrome
Completed·—·Phase 3·NCT00446147·389 enrolled
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
Completed·—·Phase 3·NCT00245050·34 enrolled
Acetylated Natural Nucleotides in Treating Hand-foot Syndrome
Completed·—·N/A·NCT04592731·21 enrolled
Topical Antiperspirant for Hand-Foot Syndrome
Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00213993·14 enrolled
Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
Completed·Alliance for Clinical Trials in Oncology·Phase 3·NCT00296036·137 enrolled
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
Completed·Roche logoRoche·Phase 3·NCT00661102·598 enrolled
Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome
Completed·NNanometics (d.b.a. PHD Biosciences)·Phase 1/2·NCT01100463·18 enrolled
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer
Terminated·UUniversity of California, San Francisco·Phase 2·NCT00751101·24 enrolled
The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients
Terminated·HHeinrich-Heine University, Duesseldorf·Phase 2·NCT03173365·2 enrolled
Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine
Unknown status·IInstituto Brasileiro de Controle do Cancer·Phase 2·NCT04833998·54 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)